BioCardia, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
BioCardia, Inc. (BCDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.17 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-24
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $1.86, a 158.33% increase year-over-year.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-03-31 was $0.72.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-03-31 was $0.13.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.17, a 50.63% decline from fiscal 2024.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.37, a 86.65% decline from fiscal 2023.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $17.75, a 1195.62% increase from fiscal 2022.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.37, a 55.81% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.17 10-K · filed 2026-03-24 | ||||
| 2024-12-31 | $2.37 10-K · filed 2026-03-24 | ||||
| 2023-12-31 | $17.75 10-K · filed 2025-03-26 | $1.18 10-K · filed 2024-03-27 | |||
| 2022-12-31 | $1.37 10-K · filed 2024-03-27 | ||||
| 2021-12-31 | $3.10 10-K · filed 2023-03-29 | ||||
| 2020-12-31 | $1.73 10-K · filed 2022-03-29 | ||||
| 2019-12-31 | $3.87 10-K · filed 2021-03-30 | ||||
| 2018-12-31 | $15.48 10-K · filed 2020-04-09 | $1.72 10-K · filed 2019-04-02 | |||
| 2018-09-30 | $1.72 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $1.77 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $1.86 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $52.20 10-K · filed 2020-04-09 | $5.80 10-K · filed 2018-03-16 | |||
| 2017-09-30 | $6.44 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $0.57 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $0.72 10-Q · filed 2017-05-11 | ||||
| 2016-12-31 | $1.33 10-K · filed 2019-04-02 | $0.11 10-K · filed 2017-03-30 | |||
| 2012-06-30 | $0.13 10-Q · filed 2013-07-26 | ||||
| 2012-03-31 | $0.13 10-Q · filed 2013-05-10 | ||||
| 2011-12-31 | $0.13 10-K · filed 2013-03-22 | ||||
| 2011-09-30 | $0.13 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |